ERVFRD-1

Across TCGA pan-cancer cohorts, ERVFRD-1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ERVFRD-1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ERVFRD-1 RNA is repressed in tumor relative to normal tissue. In most cancer types ERVFRD-1 is over-expressed in tumor, although a few such as KIRC and LUAD show the opposite, repressed pattern.

KIRC, LUAD, and BLCA are the cancer types where ERVFRD-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERVFRD-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.869	<.001	12	view →
LUAD	Female	III,IV	−1.201	<.001	10	view →
BLCA	All	All	−0.377	.001	10	view →
COAD	Female	II,III,IV	−0.357	<.001	10	view →
KIRP	All	IV	−0.740	<.001	9	view →
LUSC	Female	II,III,IV	−1.268	<.001	8	view →
READ	All	All	−0.402	.004	7	view →
BRCA	All	III,IV	−0.444	<.001	6	view →
LIHC	Male	All	−0.156	<.001	5	view →
KICH	Male	All	−1.281	<.001	4	view →
UCEC	All	All	−0.394	<.001	4	view →
CHOL	All	All	−0.057	.014	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ERVFRD-1–KIRC

Open the KIRC breakdown →